Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.
As the wise say, no journey is smooth. Even REVLIMID’s journey has had its fair share of lows, including high prices, limited accessibility, and the recent patent expiry. Despite these challenges, REVLIMID has turned out to be a major blockbuster in multiple myeloma and is still unbeaten to this day. But will REVLIMID remain unchallenged forever, or will it eventually meet ...
